مهندسی پرتو پزشکی و هسته ای ایران
2.45K subscribers
2.54K photos
518 videos
3.33K files
648 links
کانال انجمن پرتو پزشکی
Download Telegram
January 4, 2018 — Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i Proton Therapy System including Hyperscan pencil beam scanning (PBS) technology. Hyperscan PBS introduces novel energy layer switching and automated collimation systems. These advantages enable the S250i system to deliver faster, sharper and more robust PBS proton radiation treatments.

The Mevion S250i system is a compact proton therapy system capable of delivering conformal radiation therapy treatments using Hyperscan pencil beam scanning technology. The design of Hyperscan PBS technology overcomes clinical challenges that were previously faced by first-generation PBS systems.

Pencil beam scanning systems shape the delivered radiation dose by “painting” tumors spot-by-spot and layer-by-layer with sub-atomic particles. Prior to Hyperscan PBS, scanning proton systems struggled with delivery speed, according to Mevion. Long delivery times can undermine the high precision of the treatment due to the target tumor shifting under normal organ motion such as breathing.

The Mevion S250i system is based on Mevion’s high-efficiency, low-financial-risk S250 Series platform. The core technology of the S250 Series is what the company calls the world’s only gantry mounted superconducting synchrocyclotron.

For more information:
https://www.itnonline.com/content/mevion-receives-510k-clearance-hyperscan-pencil-beam-scanning-proton-therapy


🆔 @partohair
ICRU 72 .pdf
3.6 MB
ICRU report No.72
Dosimetry of beta rays and Low-energy photons for Brachytherapy with sealed sources

🆔 @partohair
🔺 "در تمام طول عُمرم با تهدید مرگ زودرس زندگی کرده ام، برای همین است از اتلاف وقت بیزارم"

👤استیون_هاوکینگ

8 ژانویه زادروز استیون هاوکینگ، نابغه فیزیک بریتانیایی

🆔: @partohair
MEDraysintell Downgrades Proton Therapy Market Projection for 2030

More information 👇

🆔 @partohair
Number of treatment rooms expected by 2030 drops from 1,200 to 900, accounting for financial, regulatory considerations

January 2, 2018 — MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200 to 900. The company said this still represents a 12 percent annual growth from 2017 to 2030, and the need to open an average of more than 50 proton therapy treatment rooms every year from 2018 to 2030.

However, with the growing clinical evidence regarding the efficacy of particle therapy that will progressively be used to treat a broader number of indications, there is room for a further acceleration of the market especially if the industry brings the cost of equipment down, according to the report.

MEDraysintell is delaying the release of the fifth edition of its Proton Therapy World Market Report and Directory to mid-January 2018, when all the latest information will be collected for the last month of 2017. The new edition will provide a comprehensive review of the world market dynamics, with an analysis of both past evolutions and future trends to the year 2030, including a detailed profile of all promoters, manufacturers or developers of proton and carbon therapy equipment.

For more information :
https://www.itnonline.com/content/medraysintell-downgrades-proton-therapy-market-projection-2030

🆔 @partohair